Drugs / BZ019
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04250324 | Nov 2019 → Aug 2022 | large B-cell lymphoma | Shanghai Cell Therapy Group Co.,Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04067414 | Jun 2018 → Jun 2021 | high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05472610 | Jun 2021 → Jan 2023 | large B-cell lymphoma | Shanghai Mengchao Cancer Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-04-11 | Shanghai Cell Therapy Group Co.,Ltd | Regulatory 国内首家非病毒载体CAR-T细胞治疗产品获许可进入临床试验！ shcell.com ↗
4月11日，BZ019正式获得临床试验许可，用于CD19阳性的成人复发或难治性弥漫大B细胞淋巴瘤，包括原发纵膈大B细胞淋巴瘤及发生转化的滤泡性淋巴瘤的临床试验。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-04-11 | Shanghai Cell Therapy Group Co.,Ltd | 国内首家非病毒载体CAR-T细胞治疗产品获许可进入临床试验！ shcell.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BZ019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04067414 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T Cells” NCT04067414 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT04250324 ↗ |
| Target | CD19 | “CD19-targeted” NCT04067414 ↗ |